Skip to main content

Table 1 Baseline patient characteristics

From: Comparison of serious inhaler technique errors made by device-naïve patients using three different dry powder inhalers: a randomised, crossover, open-label study

Characteristic

Pulmojet vs. Diskus

 

Pulmojet vs. Turbohaler

 

First randomised device

First randomised device

Pulmojet

Diskus

Pulmojet

Turbohaler

(n = 136)

(n = 141)

(n = 74)

(n = 70)

Female sex, n (%)

89 (65.4)

91 (64.5)

32 (43.2)

35 (50.0)

Age, mean (SD)

52.5 (10.9)

51.4 (10.5)

60.7 (10.1)

59.5 (11.7)

BMI (kg/m2), mean (SD)

29.5 (6.9)

30.4 (6.6)

29.4 (7.3)

28.1 (7.1)

Smoking status, n (%)

 Current smoker

21 (15.4)

25 (17.7)

14 (18.9)

23 (32.9)

 Ex-smoker

50 (36.8)

47 (33.3)

43 (58.1)

34 (48.6)

 Non-smoker

65 (47.8)

69 (48.9)

17 (23.0)

13 (18.6)

Diagnosis, n (%)

 Asthma

118 (86.8)

114 (80.9)

23 (31.1)

29 (41.4)

 COPD

17 (12.5)

23 (16.3)

51 (68.9)

41 (58.6)

 Asthma & COPD

1 (0.7)

4 (2.8)

0 (0)

0 (0)

FEV1 %predicted, mean (SD)b

84 (21)

84 (22)

69 (23)

70 (25)

FEV1/FVC, mean (SD)b

0.78 (0.15)

0.75 (0.15)

0.63 (0.16)

0.66 (0.17)

Oral corticosteroid courses, n (%)a

 1 course

21 (15.6)

17 (12.1)

11 (15.1)

22 (31.9)*

 ≥2 courses

21 (15.6)

14 (9.9)

15 (20.5)

17 (24.6)

Inpatient admission, n (%)a

 ≥1 admissions

10 (7.4)

6 (4.3)

5 (6.8)

3 (4.3)

Emergency department attendance, n (%)a

 ≥1 visits

11 (8.1)

8 (5.7)

3 (4.1)

2 (2.9)

  1. COPD chronic obstructive pulmonary disease, FEV 1 forced expiratory volume in 1 s, FVC forced vital capacity
  2. 2 test p < 0.05 for the two-way comparison; all other comparisons were non-significant
  3. aPatient-reported with regard to prior year
  4. bFEV1 and FEV1/FVC data were available for 128 (94 %) and 128 (91 %) of patients first randomised to Pulmojet and Diskus, respectively, and for 71 (96 %) and 68 (97 %) patients first randomised to Pulmojet and Turbohaler, respectively